Disorder | Daily dosage | Initiation of treatment | Treatment Duration
---|---|---|---
Vascular dementia | 10 – 30 ml | as soon as possible | 2 – 4 cycles / year
Alzheimer’s disease | 20 – 50 ml | as soon as possible | 7– 30 days
Stroke | 20 – 50 ml | as soon as possible | 10 – 21 days

Clinical benefits for patients and caregivers

1. **Decrease rate cognitive decline**
2. **Improvement of memory and concentration**
3. **Stop action in sexual life**
4. **Live a fully independent life**
5. Reduced support from caregivers needed
6. **Person remains cognitively and the destruction of personality**
7. **Improve quality of life**

**Cerebrolysin®** is a multi-modal neuropeptide drug that helps to maintain the independence of patients suffering from neurocognitive disorders.

**Effective treatment for Neurocognitive Disorders with Cerebrolysin®**

**Diagnostic problems**

**Lack of tests**

**Lack of solid criteria/biomarkers**

**No matter of course of the disease**

**No matter of type of neurocognitive disorder**

**No matter of stage of the disease**

**Cerebrolysin® FITS TO ALL**

**Cognitive impairment**

**Activities of daily living**

**Global cognition**

**Behavior & psychiatric symptoms**

**Dementia**

**Moderate Alzheimer**

**Severe Alzheimer**

**Mixed dementia**

**Vascular dementia**

**CEREBROLYSIN FITS TO ALL**

**STROKE**

**TB**

**NEUROCOGNITIVE DISORDERS**
Cerebrolysin increases level of activities of daily living

Significant superiority of Cerebrolysin compared to placebo across all time points.

Even within the follow-up period, improvements are maintained.

Cerebrolysin shows highest effect after second treatment cycle.

Placebo patients deteriorated, while patients in the Cerebrolysin group remained unchanged.

ADAS-cog improvement in the Cerebrolysin group compared to placebo.

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 8 – Mean change from baseline in ADAS-noncog scores in patients treated with different doses of Cerebrolysin or placebo, Alvarez et al. 2006 (AD)

Figure 7 – Change from baseline in the Neuropsychiatric Inventory (NPI) in patients treated with Cerebrolysin or placebo.

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin increases level of activities of daily living

Significant superiority of Cerebrolysin compared to placebo across all time points.

Even within the follow-up period, improvements are maintained.

Cerebrolysin shows highest effect after second treatment cycle.

Placebo patients deteriorated, while patients in the Cerebrolysin group remained unchanged.

ADAS-cog improvement in the Cerebrolysin group compared to placebo.

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 8 – Mean change from baseline in ADAS-noncog scores in patients treated with different doses of Cerebrolysin or placebo, Alvarez et al. 2006 (AD)

Figure 7 – Change from baseline in the Neuropsychiatric Inventory (NPI) in patients treated with Cerebrolysin or placebo.

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!

Significant improvements in the NPI, with marked improvements in behaviors and psychiatric symptoms.

Areas of no change in the Cerebrolysin group, while areas of improvement shift toward the beneficial effects of Cerebrolysin.

Figure 6 – Mean change from baseline in CIBIC+ scores in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Impact of Cerebrolysin on global functions (CIBIC+) in VaD patients treated with Cerebrolysin or placebo, Guekht et al. 2011 (VD)

Cerebrolysin improves behavior & neuropsychiatric symptoms!